Feyi Ayodele, MBA, is the co-founder and CEO of CancerIQ, a fast-growing precision health platform that allows providers to identify, evaluate, and manage entire patient populations based on individual genetic risk factors. Ayodele co-founded CancerIQ in 2013 after she took a sabbatical from the finance world to work alongside her mother—renowned medical oncologist Dr. Olufunmilayo Olopade—in the Center for Clinical Cancer Genetics at the University of Chicago.
Embracing the shift to connected care, CancerIQ fully integrates with genetics laboratories, EHRs, and specialty software vendors to streamline workflow, guide clinician decision-making, and improve patient outcomes and savings. The company’s mission is to ensure more people have access to the right genetic testing services and the right preventive care so cancer can be caught earlier or the risk can be eliminated altogether. CancerIQ’s precision health platform has been adopted by more than 65 health systems and hundreds of providers across the United States, helping inform care for hundreds of thousands of patients.
In response to the COVID-19 pandemic, Ayodele led CancerIQ’s telehealth efforts to enable providers to continue to identify high-risk patients with potential cancer diagnoses, replacing lost in-person visit volume, and triaging care to avoid a second wave of COVID-19 related deaths.
In recognition of her career successes, Ayodele was named to Crain’s Chicago Business 40 under 40 list in 2019, and she has won multiple honors, including the Chicago Booth New Venture Challenge, a fellowship from Rock Health, and 1776’s Global Challenge Cup.